Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
100%(8 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_3
1
10%
Ph phase_2
1
10%
Ph phase_1
8
80%

Phase Distribution

8

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(1)
Other(1)

Detailed Status

Completed8
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (80.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)

Trials by Status

completed880%
terminated110%
unknown110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

NCT04409132
unknownphase_3

Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

NCT04239391
completedphase_1

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
completedphase_1

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

NCT03303144
terminatedphase_2

Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

NCT02905981
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04409132Phase 1

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

Completed
NCT04239391Phase 3

Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

Unknown
NCT04042324Phase 1

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

Completed
NCT03303144Phase 1

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Completed
NCT02905981Phase 2

Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

Terminated
NCT02636049Phase 1

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

Completed
NCT02909153Phase 1

Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis

Completed
NCT02767128Phase 1

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

Completed
NCT02739100Phase 1

Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Completed
NCT02595437Phase 1

Triferic Pediatric Pharmacokinetic Protocol

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10